Compound 13 was reported to be able to disrupt the interaction between 14-3-3σ and c-Abl protein and subsequently promotes c-Abl translocation into the nucleus and provide antiproliferative effects in CML cells expressing the imatinib-resistant T315I Bcr-Abl construct [111,112]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.